Oncology Animated Video

ER+ metastatic breast cancer: Elacestrant and beyond

Follow a patient's journey during and post-elacestrant treatment for ER+/HER2- metastatic breast cancer

Prof. Maria Vittoria Dieci

Prof. Maria Vittoria Dieci
Publication Date

Feb 2024

download Downloadable resources

In this second patient case video from BREAST CANCER CONNECT, Prof. Maria Vittoria Dieci delves into the continuation of a patient case with ER+/HER2- metastatic breast cancer initially presented in our first video of this series.

Throughout this journey, we'll explore what to expect after prescribing elacestrant and take a closer look at patient-reported outcomes in the EMERALD trial.

Catch up on the first video to hear Prof Francois-Clement Bidard discuss how to optimise treatment selection and make appropriate sequencing decisions for patients with ER+/HER2- metastatic breast cancer.

Clinical Takeaways

  • PROs results demonstrating no difference between treatment arms in the EMERALD trial, support elacestrant as a clinically meaningful option in this setting

  • Elacestrant has a manageable safety profile

  • If a patient progresses on elacestrant, the choice of subsequent therapy line should be based on multiple factors, including sensitivity to prior treatments, disease burden, and tumour biology. In this context, ADCs represent a new option

  • Recognise the efficacy and safety profiles of SERDs for patients with advanced or metastatic BC, and understand their place in the treatment landscape for patients with BC
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to identify and manage adverse events

Maria Vittoria Dieci, MD, is Associate Professor at the University of Padova, vice-director of the Specialization School in Medical Oncology at the same University and attending physician at the Division of Oncology 2 of the Istituto Oncologico Veneto in Padova. She specialised in Oncology in March 2012 at the University of Modena. From May 2012 to November 2013 she completed a 18-month-research experience at the Translational Research Unit (INSERM U981) of the Gustave Roussy Institute (Villejuif, France), and obtained the “Diplome Universitaire Européen en Recherche Translationnelle et Clinique en Cancérologie”. Since November 2013 she has been conducting research and clinical activity in the field of breast cancer at the University of Padova / Istituto Oncologico Veneto IRCCS.

She is panelist of the Breast Cancer Guidelines by the Italian Association of Medical Oncology. Prof Dieci’s research production from 2008 up till now consists of more than 140 papers in peer-reviewed journals.

Prof. Maria Vittoria Dieci has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Eli Lilly, Pfizer, Novartis, Roche, Exact Science, Daiichi Sankyo, Gilead, Seagen.
Programme summary
Watch the video now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology.
Endorsement
GRASP
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

publication Publication
Oncology 
LEAP-012 publication

Expert insights on multimodal treatment for intermediate HCC

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
video Video
Oncology Hemato-oncology 
Innovating relapsed refractory multiple myeloma care

Unmet needs, therapy management, and real-world experience

Experts
Assoc. Prof. María Victoria Mateos, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Elena Zamagni
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
interactive-patient-case Interactive patient case
Oncology 
NTRK fusion testing and treatment in pediatric sarcoma

Make decisions for a young patient during his cancer journey

Experts
Dr Theodore Laetsch
Endorsed by
NTRKers
  • clock 15 MIN
  • calendar Jun 2025
PRECISION ONCOLOGY CONNECT SARCOMA CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
interactive-patient-case Interactive patient case
Oncology 
Later-line treatment strategies in metastatic colorectal cancer (mCRC)

Rechallenge vs switching

Experts
Prof. Andrea Sartore-Bianchi
Endorsed by
DiCE ICAN international cancer advocacy network
  • clock 15 MIN
  • calendar Jun 2025
GI CONNECT GI NURSES CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology 
Highlights from ASCO 2025

Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Prof. Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025
COR2ED Non-accredited Independent Medical Education
The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
Explore all programmes